<DOC>
	<DOCNO>NCT00968825</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety single administration RT001 compare placebo gel treatment moderate severe lateral canthal line .</brief_summary>
	<brief_title>Safety Efficacy Study RT001 Treat Moderate Severe Lateral Canthal Lines</brief_title>
	<detailed_description>This double-blind , randomize , parallel-group , control , multi-center study evaluate efficacy safety single administration RT001 compare placebo apply bilateral application least 72 subject moderate severe Lateral Canthal Lines . Subjects randomize within site 1 2 treatment group 1:1 ratio . The efficacy safety RT001 compare placebo evaluate . Study follow-up visit occur Weeks 2 , 4 6 .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Female male , 30 60 year age Bilateral lateral canthal line rat moderate severe base Investigator Global Assessment Lateral Canthal Lines Rest Investigator Global Assessment Lateral Canthal Lines Smile Severity Scales Willing refrain receive facial filler , laser treatment , use product affect skin remodel product may cause active dermal response treatment area begin Screening End Study ( Week 6 ) Women childbearing potential must practice willing continue use effective method birth control course study Any neurological condition may place subject increase risk exposure Botulinum Toxin Type A , include peripheral motor neuropathic disease amyotrophic lateral sclerosis motor neuropathy , euromuscular junctional disorder Muscle weakness paralysis area receive study treatment Active skin disease irritation treatment area Eyelid ptosis , excessive dermatochalasis , deep dermal scar inability substantially lessen lateral canthal line treat physically spread apart Use prescription retinoid product past 3 month prior Screening Chemical peel ( medium depth deep ) past 9 month prior Screening Undergone procedure may affect lateral canthal region : periorbital surgery , brow leave related procedure , laser skin resurface soft tissue augmentation ( upper half face ) past 12 month prior Screening Screening electrocardiogram ( ECG ) abnormal clinically significant history hypokalemia , torsade de pointe , unstable angina , myocardial infarction congestive heart failure family history prolong QT Previous treatment Botulinum Toxin Type A face area Previous treatment great 200 U Botulinum Toxin Type A anywhere else body within last 6 month prior Screening Concurrent use aminoglycoside antibiotic , agent might interfere neuromuscular transmission start Screening Use topical steroid either treatment area use medication suppress immune system 30 day prior Screening continue End Study ( Week 6 ) Clinically significant laboratory value Screening</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Lateral Canthal Lines</keyword>
	<keyword>Crow 's Feet</keyword>
	<keyword>Facial Wrinkles</keyword>
</DOC>